EE-drospirenone-levomefolate calcium versus EE-drospirenone + folic acid: folate status during 24 weeks of treatment and over 20 weeks following treatment cessation
Konstanze Diefenbach,1 Dietmar Trummer,1 Frank Ebert,1 Michael Lissy,2 Manuela Koch,2 Beate Rohde,1 Hartmut Blode3 1Bayer HealthCare Pharmaceuticals, Berlin, Germany; 2Nuvisan GmbH, Neu-Ulm, Germany; 3Bayer HealthCare Pharmaceuticals Global R&D Center, Beijing, People's Republic of China...
Saved in:
Main Authors: | Diefenbach K (Author), Trummer D (Author), Ebert F (Author), Lissy M (Author), Koch M (Author), Rohde B (Author), Blode H (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2013-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The benefits of estetrol addition to drospirenone for contraception
by: Jean Michel Foidart, PhD, MD, et al.
Published: (2023) -
Drospirenon v evolyutsiigormonal'noy kontratseptsii
by: Elena Anatol'evna Mezhevitinova, et al.
Published: (2011) -
Comparison of the lipophilicity parameters of drospirenone and lynestrenol
by: Agnieszka Kusztal, et al.
Published: (2022) -
Benefits of using combined oral contraceptive with drospirenone in 24+4 overweight adolescents
by: I V Kuznetsova, et al.
Published: (2014) -
The E.E. elective at the colleges of education In Bophuthatswana
by: Pat Irwin
Published: (1987)